Big Pharma Eyes Omicron Boosters

In a recent statement to Reuters, Stephan Bancel, the CEO of Modern announced that a booster specific to omicron could be ready in time for August. Presently, the pharmaceutical giant sin the process of gathering the clinical data necessary in order to determine whether or not the vaccine will offer superior protection to the omicron variant relative to a dose from the vaccine currently available on the market.

In the past month, Moderna started clinical trials for booster doses designed specifically for the omicron variant. Initial results from the study suggest that a shot specific to omicron may not offer any stronger protection than a new dose of the current vaccine.

Bancel indicated in a recent interview that the company aims to have a booster shot ready in time for August 2022, prior to the start of the fall. Per the pharmaceutical CEO, vulnerable individuals may be in greater need of the shot at that point of the year.

In a separate announcement, the pharmaceutical firm announced plans for expanding its commercial network throughout Europe in an effort to increase sales across the continent.

In an official statement, the pharmaceutical company declared its plans to establish “a commercial presence” across Denmark, Sweden, Belgium, Poland, Norway and the Netherlands in order “to support the delivery of mRNA vaccines and therapeutics locally.”

The newly formed Moderna subsidiaries in Europe will be in addition to the company’s existing offices in Spain, France, Italy, Britain, Germany, and Switzerland.

The company also intends to boost its commercial presence throughout the rapidly expanding Asian region.

In Europe, the pharmaceutical company produces vaccines via manufacturing partnerships, with some of the most significant partnerships including Recipharm in France, ROVI in Spain, and Lonza in Switzerland and the Netherlands.

More than 800 million shots of the coronavirus vaccine were shipped by the company in 2021, and it presently has deals with other European Union (EU) nations to supply up to 460 million additional doses.

Outside of vaccines, Moderna is also currently researching and developing mRNA drugs against a broad array of different health conditions, including rare genetic diseases, cardiovascular illnesses, and cancers.